The biopharmaceutical company said an oral presentation will highlight Phase 2 results for its Nectin-4-targeting ADC in previously treated locally advanced or metastatic triple-negative breast cancer.
Mabwell said it will present Phase 2 clinical results for Bulumtatug Fuvedotin, also known as 9MW2821, at the 2026 European Society for Medical Oncology Annual Congress in Madrid. The oral presentation will cover patients with locally advanced or metastatic triple-negative breast cancer who were previously treated with Topoisomerase I inhibitor-based antibody-drug conjugates. The abstract, numbered 4640RO, is scheduled in the advanced-stage breast cancer session on October 26, 2026, from 10:15 a.m. to 11:45 a.m. local time, with Prof. ZHANG Jian of Fudan University Shanghai Cancer Center listed as presenter. Mabwell, listed in Shanghai and Hong Kong as 688062.SH and 02493.HK, describes itself as an innovation-driven biopharmaceutical company focused on oncology and aging-related diseases.